Patents by Inventor Vania Manolova
Vania Manolova has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20220363675Abstract: The invention relates to novel compounds of the general formula (I), with Het-2 being an optionally substituted bicyclic heteroaryl of the formula pharmaceutical compositions comprising them and the use thereof as medicaments, in particular for the use as ferroportin inhibitors, more particularly for the use in the prophylaxis and/or treatment of diseases caused by a lack of hepcidin or iron metabolism disorders, such as particularly iron overload states such as in particular thalassemia and hemochromatosis.Type: ApplicationFiled: June 7, 2021Publication date: November 17, 2022Inventors: Franz Dürrenberger, Michael Burgert, Susanna Burckhardt, Wilm Buhr, Aris Kalogerakis, Stefan Reim, Vania Manolova, Susan Boyce, Christopher John Yarnold, Paula Pena, Jon Shepherd, Cristina Lecci, Richard Jarjes-Pike, John Scott
-
Publication number: 20220323416Abstract: The invention relates to the use of ferroportin inhibitor compounds of the general formula (I) for preventing and treating kidney injuries, such as in particular acute kidney injuries, and the symptoms and pathological conditions associated therewith.Type: ApplicationFiled: July 17, 2020Publication date: October 13, 2022Inventors: Vania Manolova, Franz Dürrenberger
-
Publication number: 20220274973Abstract: The invention relates to compounds of the formula and pharmaceutically acceptable salts thereof for the use in the treatment of sickle cell disease and for the use in preventing and treating vascular inflammation and vaso-occlusion.Type: ApplicationFiled: October 22, 2020Publication date: September 1, 2022Inventors: Vania Manolova, Franz Dürrenberger, Naja Nyffenegger
-
Publication number: 20220273634Abstract: The invention relates to the use of ferroportin inhibitor compounds of the general formula (I) for treating transfusion-dependent ?-thalassemia.Type: ApplicationFiled: July 17, 2020Publication date: September 1, 2022Inventors: Vania Manolova, Naja Nyffenegger, Patrick Altermatt, Franz Dürrenberger
-
Patent number: 11066399Abstract: The invention relates to novel compounds of the general formula (I), with Het-2 being an optionally substituted bicyclic heteroaryl of the formula pharmaceutical compositions comprising them and the use thereof as medicaments, in particular for the use as ferroportin inhibitors, more particularly for the use in the prophylaxis and/or treatment of diseases caused by a lack of hepcidin or iron metabolism disorders, such as particularly iron overload states such as in particular thalassemia and hemochromatosis.Type: GrantFiled: December 3, 2020Date of Patent: July 20, 2021Assignee: Vifor (International) AGInventors: Franz Dürrenberger, Michael Burgert, Susanna Burckhardt, Wilm Buhr, Aris Kalogerakis, Stefan Reim, Vania Manolova, Susan Boyce, Christopher John Yarnold, Paula Pena, Jon Shepherd, Cristina Lecci, Richard Jarjes-Pike, John Scott
-
Publication number: 20210139472Abstract: The invention relates to novel compounds of the general formula (I), with Het-2 being an optionally substituted bicyclic heteroaryl of the formula pharmaceutical compositions comprising them and the use thereof as medicaments, in particular for the use as ferroportin inhibitors, more particularly for the use in the prophylaxis and/or treatment of diseases caused by a lack of hepcidin or iron metabolism disorders, such as particularly iron overload states such as in particular thalassemia and hemochromatosis.Type: ApplicationFiled: December 3, 2020Publication date: May 13, 2021Applicant: Vifor (International) AGInventors: Franz Dürrenberger, Michael Burgert, Susanna Burckhardt, Wilm Buhr, Aris Kalogerakis, Stefan Reim, Vania Manolova, Susan Boyce, Christopher John Yarnold, Paula Pena, Jon Shepard, Cristina Lecci, Richard Jarjes-Pike, John Scott
-
Patent number: 11001579Abstract: The invention relates to novel compounds of the general formula (I), with Het-2 being an optionally substituted bicyclic heteroaryl of the formula pharmaceutical compositions comprising them and the use thereof as medicaments, in particular for the use as ferroportin inhibitors, more particularly for the use in the prophylaxis and/or treatment of diseases caused by a lack of hepcidin or iron metabolism disorders, such as particularly iron overload states such as in particular thalassemia and hemochromatosis.Type: GrantFiled: June 12, 2019Date of Patent: May 11, 2021Assignee: Vifor (International) AGInventors: Franz Dürrenberger, Michael Burgert, Susanna Burckhardt, Wilm Buhr, Aris Kalogerakis, Stefan Reim, Vania Manolova, Susan Boyce, Christopher John Yarnold, Paula Pena, Jon Shepherd, Cristina Lecci, Richard Jarjes-Pike, John Scott
-
Patent number: 10738041Abstract: The invention relates to novel ferroportin inhibitors of the general formula (I) pharmaceutical compositions comprising them and the use thereof as medicaments, in particular for the prophylaxis and/or treatment of diseases caused by a lack of hepcidin or iron metabolism disorders, such as particularly iron overload states such as in particular thalassemia and hemochromatosis.Type: GrantFiled: October 21, 2016Date of Patent: August 11, 2020Assignee: Vifor (International) AGInventors: Franz Dürrenberger, Wilm Buhr, Susanna Burckhardt, Michael Burgert, Aris Kalogerakis, Stefan Reim, Vania Manolova, Susan Boyce, Christopher John Yarnold, Paula Pena, Jon Shepherd, Cristina Lecci, Richard Jarjes-Pike, John Scott
-
Publication number: 20190345151Abstract: The invention relates to novel compounds of the general formula (I), with Het-2 being an optionally substituted bicyclic heteroaryl of the formula pharmaceutical compositions comprising them and the use thereof as medicaments, in particular for the use as ferroportin inhibitors, more particularly for the use in the prophylaxis and/or treatment of diseases caused by a lack of hepcidin or iron metabolism disorders, such as particularly iron overload states such as in particular thalassemia and hemochromatosis.Type: ApplicationFiled: June 12, 2019Publication date: November 14, 2019Inventors: Franz Dürrenberger, Michael Burgert, Susanna Burckhardt, Wilm Buhr, Aris Kalogerakis, Stefan Reim, Vania Manolova, Susan Boyce, Christopher John Yarnold, Paula Pena, Jon Shepherd, Cristina Lecci, Richard Jarjes-Pike, John Scott
-
Patent number: 10364239Abstract: The invention relates to novel compounds of the general formula (A-I), with Het-2 being an optionally substituted bicyclic heteroaryl of the formula (AA) pharmaceutical compositions comprising them and the use thereof as medicaments, in particular for the use as ferroportin inhibitors, more particularly for the use in the prophylaxis and/or treatment of diseases caused by a lack of hepcidin or iron metabolism disorders, such as particularly iron overload states such as in particular thalassemia and hemochromatosis.Type: GrantFiled: October 21, 2016Date of Patent: July 30, 2019Assignee: Vifor (International) AGInventors: Franz Dürrenberger, Michael Burgert, Susanna Burckhardt, Wilm Buhr, Aris Kalogerakis, Stefan Reim, Vania Manolova, Susan Boyce, Christopher John Yarnold, Paula Pena, Jon Shepherd, Cristina Lecci, Richard Jarjes-Pike, John Scott
-
Publication number: 20180319783Abstract: The invention relates to novel compounds of the general formula (A-I), with Het-2 being an optionally substituted bicyclic heteroaryl of the formula (AA) pharmaceutical compositions comprising them and the use thereof as medicaments, in particular for the use as ferroportin inhibitors, more particularly for the use in the prophylaxis and/or treatment of diseases caused by a lack of hepcidin or iron metabolism disorders, such as particularly iron overload states such as in particular thalassemia and hemochromatosis.Type: ApplicationFiled: October 21, 2016Publication date: November 8, 2018Inventors: Franz Dürrenberger, Michael Burgert, Susanna Burckhardt, Wilm Buhr, Aris Kalogerakis, Stefan Reim, Vania Manolova, Susan Boyce, Christopher John Yarnold, Paula Pena, Jon Shepherd, Cristina Lecci, Richard Jarjes-Pike, John Scott
-
Publication number: 20180297991Abstract: The invention relates to novel ferroportin inhibitors of the general formula (I) pharmaceutical compositions comprising them and the use thereof as medicaments, in particular for the prophylaxis and/or treatment of diseases caused by a lack of hepcidin or iron metabolism disorders, such as particularly iron overload states such as in particular thalassemia and hemochromatosis.Type: ApplicationFiled: October 21, 2016Publication date: October 18, 2018Inventors: Franz Dürrenberger, Wilm Buhr, Susanna Burckhardt, Michael Burgert, Aris Kalogerakis, Stefan Reim, Vania Manolova, Susan Boyce, Christopher John Yarnold, Paula Pena, Jon Shepherd, Cristina Lecci, Richard Jarjes-Pike, John Scott
-
Publication number: 20140056933Abstract: The application is related to compositions and methods for the treatment of hypersensitivity, wherein the compositions comprise a particle packaged with immunostimulatory nucleic acids. The compositions of the invention are particularly useful in the treatment of atopic eczema, asthma and IgE-mediated allergy (type I allergy), especially pollen allergy and house dust allergy.Type: ApplicationFiled: July 22, 2013Publication date: February 27, 2014Inventors: Wolfgang Renner, Martin F. Bachmann, Indulis Cielens, Conrad Johannes Coester, Klaus Dietmeier, Sebastian Fuchs, Vania Manolova, Patrik Maurer, Paul Pumpens, Regina Renhofa, Alain Tissot, Yu Zou
-
Patent number: 8574564Abstract: The application is related to compositions and methods for the treatment of hypersensitivity, wherein the compositions comprise a particle packaged with immunostimulatory nucleic acids. The compositions of the invention are particularly useful in the treatment of atopic eczema, asthma and IgE-mediated allergy (type I allergy), especially pollen allergy and house dust allergy.Type: GrantFiled: October 8, 2009Date of Patent: November 5, 2013Assignee: Cytos Biotechnology AGInventors: Wolfgang A. Renner, Martin F. Bachmann, Indulis Cielens, Conrad Johannes Coester, Klaus Dietmeier, Sebastian Fuchs, Vania Manolova, Patrik Maurer, Paul Pumpens, Regina Renhofa, Alain Tissot, Yu Zou
-
Publication number: 20110097417Abstract: The present invention is related to the fields of molecular biology, virology, immunology and medicine. The invention provides a modified virus-like particle (VLP) comprising a VLP which can be loaded with immunostimulatory substances, in particular with DNA oligonucleotides containing non-methylated C and G (CpGs), and particular peptides derived from MelanA linked thereto. Such CpG-VLPs are dramatically more immunogenic than their CpG-free counterparts and induce enhanced B and T cell responses. The immune response against MelanA peptide analogues optionally coupled, fused or attached otherwise to the VLPs is similarly enhanced as the immune response against the VLP itself. In addition, the T cell responses against the MelanA peptide analogues are especially directed to the Th1 type. Antigens attached to CpG-loaded VLPs may therefore be ideal vaccines for prophylactic or therapeutic vaccination against allergies, tumors and other self-molecules and chronic viral diseases.Type: ApplicationFiled: May 11, 2009Publication date: April 28, 2011Applicant: Cytos Biotechnology AGInventors: Martin F. BACHMANN, Vania Manolova, Edwin Meijerink, Karl G. Proba, Katrin Schwarz
-
Publication number: 20100303846Abstract: The application is related to compositions and methods for the treatment of hypersensitivity, wherein the compositions comprise a particle packaged with immunostimulatory nucleic acids. The compositions of the invention are particularly useful in the treatment of atopic eczema, asthma and IgE-mediated allergy (type I allergy), especially pollen allergy and house dust allergy.Type: ApplicationFiled: October 8, 2009Publication date: December 2, 2010Applicant: Cytos Biotechnology AGInventors: Wolfgang A. RENNER, Martin F. BACHMANN, Indulis CIELENS, Conrad Johannes COESTER, Klaus DIETMEIER, Sebastian FUCHS, Vania MANOLOVA, Patrik MAURER, Paul PUMPENS, Regina RENHOFA, Alain TISSOT, Yu ZOU
-
Publication number: 20100098722Abstract: The invention relates to the finding that virus like particles (VLPs) can be loaded with immunostimulatory substances, in particular with DNA oligonucleotides containing non-methylated C and G (CpGs). Such CpG-VLPs are dramatically more immunogenic than their CpG-free counterparts and induce enhanced B and T cell responses. The immune response against antigens optionally coupled, fused or attached otherwise to the VLPs is similarly enhanced as the immune response against the VLP itself. In addition, the T cell responses against both the VLPs and antigens are especially directed to the Th1 type. Antigens attached to CpG-loaded VLPs may therefore be ideal vaccines for prophylactic or therapeutic vaccination against allergies, tumors and other self-molecules and chronic viral diseases.Type: ApplicationFiled: March 24, 2009Publication date: April 22, 2010Inventors: Martin F. BACHMANN, Andreas Cornelius, Vania Manolova, Patrik Maurer, Edwin Meijerink, Karl G. Proba, Katrin Schwarz
-
Patent number: 7537767Abstract: The present invention is related to the fields of molecular biology, virology, immunology and medicine. The invention provides a modified virus-like particle (VLP) comprising a VLP which can be loaded with immunostimulatory substances, in particular with DNA oligonucleotides containing non-methylated C and G (CpGs), and particular peptides derived from MelanA linked thereto. Such CpGVLPs are dramatically more immunogenic than their CpG-free counterparts and induce enhanced B and T cell responses. The immune response against MelanA peptide analogues optionally coupled, fused or attached otherwise to the VLPs is similarly enhanced as the immune response against the VLP itself. In addition, the T cell responses against the MelanA peptide analogues are especially directed to the Thl type. Antigens attached to CpG-loaded VLPs may therefore be ideal vaccines for prophylactic or therapeutic vaccination against allergies, tumors and other self-molecules and chronic viral diseases.Type: GrantFiled: March 25, 2004Date of Patent: May 26, 2009Assignee: Cytis Biotechnology AGInventors: Martin F. Bachmann, Vania Manolova, Edwin Meijerink, Karl G. Proba, Katrin Schwartz
-
Patent number: 7517520Abstract: The invention relates to the finding that virus like particles (VLPs) can be loaded with immunostimulatory substances, in particular with DNA oligonucleotides containing non-methylated C and G (CpGs). Such CpG-VLPs are dramatically more immunogenic than their CpG-free counterparts and induce enhanced B and T cell responses. The immune response against antigens optionally coupled, fused or attached otherwise to the VLPs is similarly enhanced as the immune response against the VLP itself. In addition, the T cell responses against both the VLPs and antigens are especially directed to the Th1 type. Antigens attached to CpG-loaded VLPs may therefore be ideal vaccines for prophylactic or therapeutic vaccination against allergies, tumors and other self-molecules and chronic viral diseases.Type: GrantFiled: March 25, 2004Date of Patent: April 14, 2009Assignee: Cytos Biotechnology AGInventors: Vania Manolova, Martin F. Bachmann, Andreas Cornelius, Patrik Maurer, Edwin Meijerink, Karl G. Proba, Katrin Schwarz
-
Publication number: 20090074851Abstract: Liposomes are known to enhance the activity of K- (B-) type CpGs which trigger the production of IL-12. In the present invention, the surprising finding was made that liposomes also enhance the activity of D- (A-) type CpGs, leading to the production of IFN? in vivo. These findings are relevant for the humans situation, since IFN? rather than IL-12 is the key cytokine for the induction of Th1 responses and anti-viral protection in humans.Type: ApplicationFiled: July 11, 2008Publication date: March 19, 2009Applicant: Cytos Biotechnology AGInventors: Martin F. BACHMANN, Vania Manolova, Tazio Storni